Athersys (NASDAQ:ATHX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a report published on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

ATHX stock opened at $0.01 on Wednesday. The stock has a market capitalization of $345,626.40, a price-to-earnings ratio of 0.00 and a beta of -0.90. The business’s fifty day moving average price is $0.01 and its two-hundred day moving average price is $0.07. Athersys has a fifty-two week low of $0.01 and a fifty-two week high of $1.99.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. UBS Group AG increased its position in shares of Athersys by 30.1% in the second quarter. UBS Group AG now owns 724,652 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 167,756 shares during the period. Geode Capital Management LLC increased its position in shares of Athersys by 96.6% in the second quarter. Geode Capital Management LLC now owns 155,297 shares of the biopharmaceutical company’s stock worth $135,000 after purchasing an additional 76,297 shares during the period. Sequoia Financial Advisors LLC increased its position in shares of Athersys by 114.6% in the first quarter. Sequoia Financial Advisors LLC now owns 154,305 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 82,417 shares during the period. Virtu Financial LLC increased its position in shares of Athersys by 248.2% in the second quarter. Virtu Financial LLC now owns 323,282 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 230,436 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Athersys by 67.3% in the fourth quarter. Renaissance Technologies LLC now owns 99,936 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 40,200 shares during the period. Institutional investors own 19.35% of the company’s stock.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.